Rigosertib sodium is under clinical development by Traws Pharma and currently in Phase II for Lung Adenocarcinoma. According to GlobalData, Phase II drugs for Lung Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Rigosertib sodium LoA Report. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Likelihood of Approval and Phase Transition Success Rate Model - Rigosertib Sodium in Lung Adenocarcinoma

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Rigosertib sodium overview

Rigosertib (Estybon, ON 01910.Na and SyB L-1101) is under development for the treatment of metastatic kirsten rat sarcoma positive (KRAS+) lung adenocarcinoma, higher-risk myelodysplastic syndromes (MDS), recessive dystrophic epidermolysis bullosa associated locally advanced/metastatic squamous cell carcinoma, chronic myelomonocytic leukemia (CMML), neuroblastoma, rhabdomyosarcoma ,non small cell lung cancer and various RASopathies (unspecified). It is a administered orally and intravenously. It acts by targeting phosphoinositide 3-kinase (PI3K) and polo-like kinase (PLK).
It was also under development for the treatment of metastatic melanoma, metastatic pancreatic cancer, ovarian cancer, mantle cell lymphoma, refractory/relapsed multiple myeloma, refractory/relapsed chronic lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia and hairy cell leukemia. It was also under development for acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), myeloproliferative neoplasms including myelofibrosis, essential thrombocythemia, Polycythemia Vera, Juvenile Myelomonocytic Leukemia (JMML), Coronavirus Disease 2019 (COVID-19), Renal Cell Carcinoma, Human Papillomavirus (HPV) Associated Cancer, Esophageal Squamous Cell Carcinoma (ESCC), skin squamous cancer,  colorectal cancer, cervical squamous cell cancer, penile squamous cell cancer and anal squamous cell cancer.

Traws Pharma overview

Traws Pharma, formerly known as Onconova Therapeutics, is a clinical-stage biopharmaceutical company. It develops small-molecule oral therapies for respiratory viral diseases and cancer. In the respiratory sector, it is advancing TRX01 (ratutrelvir), targeting SARS-CoV-2 Mpro, and TRX100 (tivoxavir marboxil), effective against drug-resistant influenza strains. In oncology, Traws is developing narazaciclib, a multi-kinase CDK4-plus inhibitor for refractory endometrial and metastatic breast cancer, currently in Phase 1/2 trials and rigosertib for the treatment of epidermolysis bullosa-associated squamous cell carcinoma. The company utilizes a proprietary chemistry platform enhanced by artificial intelligence (AI) and machine learning to optimize compound development and minimize side effects. Traws Pharma is headquartered in Newtown, Pennsylvania, the US.

For a complete picture of Rigosertib sodium’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 12 April 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.